<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01375296</url>
  </required_header>
  <id_info>
    <org_study_id>RJH20100918</org_study_id>
    <nct_id>NCT01375296</nct_id>
  </id_info>
  <brief_title>China Made Sirolimus Eluting Stent for Intermediate Lesion</brief_title>
  <acronym>SESIL</acronym>
  <official_title>China Made Sirolimus Eluting Stent for Treatment of Coronary Intermediate Lesion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <brief_summary>
    <textblock>
      Sirolimus-eluting stent (SES) has been proven to improve outcomes in patients with
      significant coronary artery diseae(&gt; 70% lumen diameter narrowing). But, acute coronary
      syndrome may occur in those with intermediate lesions(50%-70% lumen diameter narrowing), and
      the effect of SES in these patients remains unclear. Here the investigators hypothesize that
      application of China-made SES may improve the clinical outcomes in these setting.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">November 2011</completion_date>
  <primary_completion_date type="Anticipated">October 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>target vessel failure</measure>
    <time_frame>12 months</time_frame>
    <description>defined as the occurrence of any of the following within 12 months after the index procedure: death from cardiac causes, Q-wave or non-Q-wave myocardial infarction, or revascularization of the target vessel (emergency or elective coronaryartery bypass grafting [CABG] or repeated percutaneous transluminal coronary angioplasty [PTCA]).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>major adverse cardiac events</measure>
    <time_frame>12 months</time_frame>
    <description>including cardiac death, re-infarction and target vessel revascularization.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>SES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>including two types of China-made SES, i.e. Firebird 2 (cobalt-alloy platform with durable polymer coating sirolimus-eluting stent) and Excel (stainless steel platform with biodegradable polymer coating sirolimus-eluting stent).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>medicine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>China-made SES (Firebird 2 and Excel)</intervention_name>
    <description>patients with coronary 50-70% narrowing treated with China-made SES stent,i.e. Firebird 2 (cobalt-alloy platform with durable polymer coating sirolimus-eluting stent) and Excel (stainless steel platform with biodegradable polymer coating sirolimus-eluting stent).</description>
    <arm_group_label>SES</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>routine medicine</intervention_name>
    <description>patients with coronary 50-70% narrowing treated with routine medicine</description>
    <arm_group_label>medicine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-80 years old

          -  both gender

          -  native coronary lesion

          -  narrowing 50-70%

          -  vessel size 2.5-4.0 in diameter

        Exclusion Criteria:

          -  without informed consent,

          -  ST elevation myocardial infarction within 7 days,

          -  left main lesion,

          -  by-pass graft,

          -  restenosis

          -  abnormal liver function before randomization,

          -  active hepatitis or muscular disease,

          -  impaired renal function with serum creatinine level &gt; 3mg/dl ,

          -  impaired left ventricular function with LVEF &lt; 30%,

          -  participate in other studies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ruiyan Zhang, MD</last_name>
    <phone>862164370045</phone>
    <phone_ext>665215</phone_ext>
    <email>zhangruiyan@263.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>ruijin hospital, Shanghai Jiao Tong University, School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruiyan Zhang, MD</last_name>
      <phone>862164370045</phone>
      <phone_ext>665215</phone_ext>
      <email>zhangruiyan@263.net</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2011</study_first_submitted>
  <study_first_submitted_qc>June 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2011</study_first_posted>
  <last_update_submitted>June 16, 2011</last_update_submitted>
  <last_update_submitted_qc>June 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Weifeng Shen</name_title>
    <organization>Ruijin hospital, shanghai jiao tong university school of medicine</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

